CA
NZ
UK
AU
IND
US
…
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
ResMed Inc designs and sells respiratory care devices, masks and cloud-based software used to diagnose and treat sleep apnea and other chronic respiratory conditions. Long-term growth drivers include demographic trends increasing sleep-disorder prevalence, expansion of home healthcare and recurring revenue from consumables and digital services, which could support steady demand and scale advantages.
Investors should monitor regulatory and reimbursement pressure, competition and potential product recalls or quality and supply-chain disruptions that could affect sales and margins.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | 1961.56M | 1677.57M | 1264.80M | 1101.66M | 960.48M |
| Net income | 1556.74M | 1400.72M | 1020.95M | 897.56M | 897.56M |
| Selling general administrative | - | 991.02M | 917.14M | 874.00M | 739.37M |
| Gross profit | 3481.06M | 3054.97M | 2655.30M | 2355.66M | 2024.31M |
| Reconciled depreciation | - | 235.81M | 216.21M | 197.56M | 193.84M |
| Ebit | 1962.10M | 1687.39M | 1310.51M | 1141.97M | 1000.29M |
| Ebitda | 2211.61M | 1923.20M | 1526.71M | 1339.54M | 1194.13M |
| Depreciation and amortization | 249.51M | 235.81M | 216.21M | 197.56M | 193.84M |
| Operating income | 1962.10M | 1685.36M | 1384.12M | 1131.87M | 1000.29M |
| Other operating expenses | 3815.47M | 3460.96M | 3365.40M | 3071.00M | 2577.84M |
| Interest expense | - | - | 45.71M | - | 0.00M |
| Tax provision | - | 276.84M | 243.85M | 204.11M | 181.05M |
| Interest income | - | 2.54M | 51.60M | 44.72M | 43.00M |
| Net interest income | - | 4.11M | -45.71M | -47.38M | -22.31M |
| Income tax expense | 404.82M | 276.84M | 243.85M | 204.11M | 181.05M |
| Total revenue | 5777.57M | 5146.33M | 4685.30M | 4222.99M | 3578.13M |
| Total operating expenses | 1518.96M | 1369.61M | 3301.18M | 1203.66M | 1024.03M |
| Cost of revenue | 2296.51M | 2091.36M | 2029.99M | 1867.33M | 1553.82M |
| Total other income expense net | -0.54M | -7.80M | -73.61M | -2.95M | -17.49M |
| Net income from continuing ops | - | 1400.72M | 1020.95M | 897.56M | 779.44M |
| Net income applicable to common shares | - | 1400.72M | 1020.95M | 897.56M | 779.44M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 8962.07M | 8174.39M | 6872.39M | 6751.71M | 5095.85M |
| Intangible assets | 452.74M | 3511.54M | 485.90M | 552.34M | 345.94M |
| Other current assets | 873.09M | - | 180.01M | 437.02M | 337.91M |
| Total liab | 2379.53M | 2206.53M | 2008.35M | 2621.80M | 1735.10M |
| Total stockholder equity | 6582.54M | 5967.86M | 4864.04M | 4129.90M | 3360.75M |
| Other current liab | 633.79M | - | 485.19M | 875.77M | 779.23M |
| Common stock | 0.76M | 0.76M | 0.59M | 0.59M | 0.59M |
| Capital stock | - | - | 0.59M | 0.59M | 0.59M |
| Retained earnings | 7251.98M | 6081.49M | 4991.65M | 4253.02M | 3613.74M |
| Other liab | - | - | - | 315.19M | 160.03M |
| Good will | 2909.57M | - | 2842.05M | 2770.30M | 1936.44M |
| Other assets | - | 438.96M | - | 261.31M | 202.29M |
| Cash | 1468.60M | - | 238.36M | 227.89M | 273.71M |
| Cash and equivalents | - | 1209.45M | - | - | 273.71M |
| Total current liabilities | 1394.51M | 1019.12M | 910.65M | 758.53M | 689.30M |
| Current deferred revenue | 162.84M | - | 152.55M | 138.07M | 108.67M |
| Net debt | -643.04M | - | 635.57M | 1352.02M | 643.84M |
| Short term debt | 289.09M | - | 35.18M | 31.82M | 31.77M |
| Short long term debt | - | - | 9.90M | 9.90M | 9.92M |
| Short long term debt total | 825.56M | - | 873.93M | 1579.91M | 917.55M |
| Other stockholder equity | -587.72M | -74.70M | 123.34M | 148.83M | 59.18M |
| Property plant equipment | - | 718.29M | - | 665.81M | 630.50M |
| Total current assets | 4322.87M | 3505.61M | 2357.72M | 2367.83M | 1931.48M |
| Net tangible assets | - | - | - | 807.26M | 1078.37M |
| Net receivables | 1035.78M | 939.49M | 837.27M | 704.91M | 575.95M |
| Long term debt | - | 658.39M | 697.31M | 1431.23M | 765.33M |
| Inventory | 945.40M | 927.71M | 822.25M | 998.01M | 743.91M |
| Accounts payable | 308.79M | - | 237.73M | 150.76M | 159.25M |
| Accumulated other comprehensive income | -82.48M | - | -251.53M | -272.53M | -312.75M |
| Non currrent assets other | 386.29M | - | 284.00M | 395.43M | 251.49M |
| Non current assets total | 4639.20M | - | 4514.68M | 4383.88M | 3164.38M |
| Capital lease obligations | - | - | 166.72M | 138.77M | 142.31M |
| Long term debt total | - | 658.39M | - | - | 765.33M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | -200.04M | -269.78M | -1159.85M | -13.92M |
| Change to liabilities | - | - | - | 31.34M | -247.63M |
| Total cashflows from investing activities | -557.17M | -200.04M | -269.78M | -1159.85M | -229.92M |
| Net borrowings | - | -40.00M | -730.00M | 665.00M | 122.00M |
| Total cash from financing activities | -1029.14M | -606.25M | -1119.29M | 422.87M | -128.36M |
| Change to operating activities | - | - | - | -138.12M | -168.11M |
| Net income | 1556.74M | 1400.72M | 1020.95M | 897.56M | 779.44M |
| Change in cash | 190.59M | 971.09M | 10.47M | -45.82M | -21.57M |
| Begin period cash flow | 1278.01M | 238.36M | 227.89M | 273.71M | 295.28M |
| End period cash flow | 1468.60M | 1209.45M | 238.36M | 227.89M | 273.71M |
| Total cash from operating activities | 1845.48M | 1751.59M | 1401.26M | 693.30M | 351.15M |
| Issuance of capital stock | - | 74.44M | 53.09M | 49.14M | 47.38M |
| Depreciation | 249.51M | 235.81M | 216.21M | 197.56M | 193.84M |
| Other cashflows from investing activities | 8.67M | -10.78M | -15.40M | -1025.85M | -17.18M |
| Dividends paid | 357.34M | -310.88M | -282.32M | -258.28M | 245.34M |
| Change to inventory | -10.14M | -80.17M | 172.20M | -248.83M | -311.68M |
| Change to account receivables | -98.90M | -76.68M | -134.28M | -106.51M | 19.35M |
| Sale purchase of stock | -715.41M | -300.02M | -150.01M | 1070.00M | 288.00M |
| Other cashflows from financing activities | -22.31M | -29.79M | -10.05M | -32.99M | -52.41M |
| Change to netincome | - | - | - | 60.31M | 85.94M |
| Capital expenditures | 159.72M | 100.64M | 114.86M | 134.00M | 156.04M |
| Change in working capital | -75.87M | 16.74M | 44.78M | -462.13M | -708.08M |
| Stock based compensation | - | 91.66M | 80.18M | 71.14M | 65.26M |
| Other non cash items | 115.10M | 6.66M | 39.13M | -11.05M | 20.69M |
| Free cash flow | 1685.76M | 1650.95M | 1286.40M | 559.30M | 195.11M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| RMD Resmed Inc |
0.14 0.40% |
34.75 | 21.77 | 19.57 | 8.49 | 5.53 | 5.50 | 14.10 |
| FPH Fisher & Paykel Healthcare Corporation Ltd |
0.31 0.80% |
39.20 | 55.56 | 48.54 | 9.91 | 12.92 | 11.78 | 33.96 |
| ANN Ansell Ltd |
0.14 0.31% |
45.66 | 21.27 | 22.73 | 2.99 | 2.16 | 2.24 | 12.03 |
| NAN Nanosonics Ltd |
-0.06 2.03% |
2.89 | 49.17 | 78.12 | 4.33 | 4.02 | 3.64 | 24.30 |
| AHC Austco Healthcare Ltd |
-0.01 3.64% |
0.27 | 13.75 | 16.31 | 1.09 | 1.63 | 0.94 | 5.71 |
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123
858-836-5000
11370
| Name | Title | Year Born |
|---|---|---|
| Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD | Founder & Non-Exec. Chairman | 1942 |
| Mr. Michael J. Farrell BE, MBA, SM | CEO & Director | 1972 |
| Mr. Robert A. Douglas | Pres & COO | 1960 |
| Mr. Brett A. Sandercock | Chief Financial Officer | 1967 |
| Mr. David B. Pendarvis | Chief Admin. Officer, Global Gen. Counsel & Corp. Sec. | 1959 |
| Mr. Kaushik Ghoshal | Pres of SaaS Bus. | 1968 |
| Ms. Urvashi Tyagi | Chief Technology Officer | NA |
| Ms. Constance C. Bienfait | Director of Investor Relations | NA |
| Ms. Amy Wakeham | VP of Investor Relations & Corp. Communications | NA |
| Ms. Vered Keisar | Chief People Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...